Life sciences consultancy plans to expand, add 38 jobs
Indianapolis-based Pearl Pathways, founded by two former Eli Lilly employees, plans to move into new space in March and add the jobs by 2016.
Health Care Businesses
Articles
Once-thriving drug lab in turnaround mode
Two years ago, executives at AIT Laboratories “took their eye off the ball,” and watched the company’s business plummet 29 percent in value. Now, after two years of turmoil, the drug-testing lab says it’s poised to return to the double-digit rates of growth that made it a local star.
Greenwood seeks funds back from drugmaker with big plans
Greenwood-based Elona Biotechnologies Inc., which has been trying to bring a generic version of insulin to market, was declared in default on $8.4 million in incentives from the city of Greenwood.
Lilly drug chosen for Alzheimer’s prevention study
Researchers have chosen an experimental drug by Eli Lilly and Co. for a large federally funded study testing whether it's possible to prevent Alzheimer's disease in older people at high risk of developing it.
Roche makes Fortune’s ‘Best Companies’ list
Roche Diagnostics Corp. in Indianapolis ranks 89th on the magazine’s latest “Best Companies to Work For” list and was the only Indiana-based company selected.
Lilly’s Amyvid receives European approval
European regulators approved the use of an imaging agent from Eli Lilly and Co., which can help doctors diagnose Alzheimer's disease.
Lilly competitor gets backing on diabetes drug
Johnson & Johnson, the world’s largest seller of health-care products, won the backing of U.S. advisers for a diabetes pill the company is seeking to make the first in a new family of drugs for managing blood sugar.
Lilly settles with four sisters in DES cancer case
Four sisters who claimed their breast cancer was caused by a drug their mother took during pregnancy in the 1950s reached a settlement Wednesday with Eli Lilly and Co. in the first of scores of similar claims around the country to go to trial.
Drug sold by Lilly caused cancer, women claim at Boston trial
In opening statements Tuesday, a lawyer for Indianapolis-based Lilly told the jury there is no evidence the synthetic estrogen known as DES causes breast cancer in the daughters of women who took it.
Fiscal cliff deal threatens Indiana co-op health plan
Last week’s fiscal cliff bargain in Congress dealt a potentially fatal blow to a new health insurance plan, called Remedy Indiana, that was set to launch this year.
Spotlight falls on IU Health for flu shot firings
Indiana University Health got national attention last week for its decision to dismiss eight employees for refusing to get a flu vaccination. The Indianapolis-based hospital system fired three nurses and five other employees from its IU Health Goshen Hospital.
Big drug deals expected to return in 2013
Pharmaceutical companies including Pfizer Inc., Bristol-Myers Squibb Co. and Eli Lilly and Co. could be ready to start making major acquisitions again.
Lilly’s 2013 profit forecast tops expectations
Eli Lilly and Co. forecasts its 2013 earnings will grow more than Wall Street expects even though the drugmaker will lose U.S. patent protection for two more key products in the new year.
Trial set to begin over pregnancy drug sold by Lilly
Four sisters diagnosed with breast cancer are suing Eli Lilly and Co., a former maker of DES, or diethylstilbestrol, a drug taken by their mother in the 1950s when she was pregnant. It could be the first of scores of such trials over the drug.
Lilly agrees to pay $29.4M to settle SEC bribery charges
According to a statement released by the SEC, Eli Lilly paid $6.5 million—and in some cases gave jewelry and spa treatments—to win government contracts in Brazil, China, Russia and Poland.
Indiana to receive nearly $793K in Amgen settlement
Amgen Inc. has agreed to pay Indiana nearly $793,000 as part of a larger settlement to resolve allegations it paid kickbacks to physicians who prescribed some of its drugs for unapproved uses.
Lilly OKs $1.5B share buyback, first quarter dividend
Indianapolis-based drugmaker Eli Lilly and Co. said Monday that its board authorized a $1.5 billion share-repurchase program, which the company expects to complete next year.
Health care pricing service comes to Indy
Chicago-based OkCopay Inc. posts prices offered by Indianapolis health care providers, many of which have agreed to give cash-paying patients a price roughly equivalent to those charged to insured customers. The site also includes pricing information from health care providers that do not give cash-paying patients an additional break.
Lilly discontinues late-stage trial in rheumatoid arthritis
Eli Lilly and Co. said it discontinued a last-stage trial of experimental rheumatoid arthritis drug tabalumab for lack of efficacy. Lilly is still evaluating the drug in the two other late-stage studies.
Lilly notifies Canada about NAFTA complaint on Strattera patent
Eli Lilly and Co. notified Canada it plans to file a trade complaint, claiming court decisions invalidating one of the company’s patents breach international obligations.